Welcome to our dedicated page for CME Group SEC filings (Ticker: CME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Overview of CME Group
CME Group Inc. (NASDAQ: CME) is the world's leading and most diverse derivatives marketplace, offering a comprehensive suite of products that enable businesses, investors, and institutions to manage risk and seize opportunities in global markets. Headquartered in Chicago, CME Group operates a range of exchanges that facilitate trading in futures and options across major asset classes, including interest rates, equity indexes, foreign exchange, energy, agricultural commodities, and metals. The company plays a pivotal role in global financial markets by providing liquidity, transparency, and risk management solutions.
Core Business Areas
CME Group's business is anchored on three primary pillars:
- Derivatives Trading: CME Group offers futures and options contracts on its electronic trading platform, CME Globex, as well as through open outcry and privately negotiated transactions. Its product portfolio includes global benchmarks such as U.S. Treasury futures, SOFR futures, and equity index futures tied to the S&P 500.
- Clearing Services: Through CME Clearing, the company acts as a central counterparty, mitigating counterparty credit risk for both exchange-traded and over-the-counter (OTC) derivatives. This service ensures market integrity and reduces systemic risk.
- Market Data and Analytics: CME Group provides real-time and historical market data, empowering market participants with actionable insights to optimize their trading strategies.
Global Reach and Technological Infrastructure
CME Group operates on a global scale, with a significant presence in North America, Europe, Asia-Pacific, and Latin America. Its electronic trading platform, CME Globex, facilitates seamless access to its markets, while its BrokerTec platform supports fixed-income trading, and EBS enables foreign exchange trading. The company continues to innovate through partnerships, such as its collaboration with Google Cloud, which enhances its data analytics and scalability.
Competitive Position and Differentiation
As a leader in derivatives trading, CME Group distinguishes itself through:
- Product Breadth: Offering the widest range of benchmark products across all major asset classes.
- Liquidity: Providing deeply liquid markets that attract a diverse range of participants, from institutional investors to commercial hedgers.
- Clearing Capabilities: Operating one of the world's most trusted clearinghouses, ensuring the stability and reliability of its markets.
Industry Significance
CME Group's role extends beyond trading. It fosters economic stability by enabling businesses to hedge against price volatility and geopolitical risks. Its products are integral to managing interest rate exposure, foreign exchange fluctuations, and commodity price changes. Additionally, the company contributes to market transparency and efficiency, making it a cornerstone of the global financial system.
Challenges and Strategic Focus
Operating in a highly regulated and competitive environment, CME Group faces challenges such as evolving regulatory frameworks, technological advancements, and market competition. To address these, the company focuses on innovation, expanding its product offerings (e.g., carbon credit futures, short-dated options), and strengthening its global footprint.
Commitment to Sustainability and Community
CME Group is also committed to corporate responsibility, supporting initiatives like the Race to the CME Globe in women's golf and contributing to causes such as St. Jude Children's Research Hospital. Its recent launch of carbon credit futures aligns with global efforts to address climate change.
Conclusion
With its robust infrastructure, diverse product offerings, and unwavering commitment to market integrity, CME Group remains an indispensable player in the global financial ecosystem. Its ability to adapt to changing market dynamics and innovate ensures its continued relevance and leadership in the derivatives marketplace.
CME Group director Patrick W. Maloney reported the acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Maloney now beneficially owns 4,098 shares directly. The filing indicates this was a planned acquisition under the company's director compensation program rather than an open market purchase.
- Transaction Code: A (Grant/Award)
- Ownership Form: Direct (D)
- Filing Type: Form 4 (Statement of Changes in Beneficial Ownership)
- Total Transaction Value: $145,251.96
CME Group director Harold Eugene Ford Jr. reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Ford's direct beneficial ownership increased to 2,091 shares. The Form 4 filing indicates this was a standard director compensation grant, demonstrating ongoing alignment between board member and shareholder interests.
- Transaction Type: Stock Award (Code A)
- Role: Director (Non-Employee)
- Filing Type: Individual
- Ownership: Direct
CME Group director Elizabeth A. Cook reported insider trading activity on June 25, 2025. The transaction involved the acquisition of 532 shares of Class A Common Stock at a price of $273.03 per share through a trust, granted pursuant to the CME Group Director Stock Plan.
Following the transaction, Cook's beneficial ownership includes:
- 18,771 shares held indirectly through a trust
- 20 shares held indirectly through a joint account
The Form 4 filing was signed by Jenelle Chalmers on behalf of Elizabeth A. Cook on June 26, 2025. This transaction represents a standard director compensation grant and demonstrates continued insider investment in the company.
CME Group director Timothy S. Bitsberger reported an insider transaction on Form 4 filed June 28, 2025, disclosing activity from June 25, 2025. Key details:
- Acquired 532 shares of Class A Common Stock at $273.03 per share
- Shares were granted through the CME Group Director Stock Plan
- Following the transaction, Bitsberger directly owns 11,121 shares
This transaction represents a standard director stock grant as part of CME Group's board compensation program. The filing was signed by Jenelle Chalmers on behalf of Bitsberger on June 26, 2025. No derivative securities were involved in this transaction.
CME Group director Rahael Seifu reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted through the CME Group Director Stock Plan.
Following this transaction, Seifu now beneficially owns 4,094 shares directly. The filing indicates this was a planned compensation grant rather than an open market purchase.
Key Transaction Details:
- Transaction Type: Stock Award (Plan-Based)
- Ownership Type: Direct
- Role: Director
- Total Transaction Value: $145,251.96
CME Group director Patrick J. Mulchrone reported insider trading activity on June 25, 2025. Key details of the transaction include:
- Acquired 532 shares of Class A Common Stock at $273.03 per share through the CME Group Director Stock Plan
- Following the transaction, Mulchrone directly owns 28,485 shares
- Additionally holds 25,000 shares indirectly through spouse
The Form 4 filing indicates this was a planned acquisition under the company's director compensation program rather than an open market transaction. The filing was submitted by Jenelle Chalmers on behalf of Mulchrone on June 26, 2025, within the required reporting timeframe.
CME Group director Phyllis M. Lockett reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Lockett now beneficially owns 3,640 shares directly. The filing indicates this was a planned stock grant as part of director compensation rather than an open market purchase.
- Transaction Code: A (Grant/Award)
- Ownership Form: Direct (D)
- Filing Type: Form 4 (Statement of Changes in Beneficial Ownership)
- Total Transaction Value: Approximately $145,252
This insider transaction represents routine director compensation and does not indicate any unusual trading patterns or significant changes in ownership structure.
CME Group director Deborah J. Lucas reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Lucas now beneficially owns 3,888 shares directly. The filing indicates this was a routine director stock grant rather than an open market purchase.
Key Transaction Details:
- Transaction Type: Stock Award (Code A)
- Ownership Type: Direct
- Role: Director
- Total Transaction Value: $145,251.96
CME Group director Bryan T. Durkin reported the acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Durkin now beneficially owns 47,207 shares directly. The filing indicates this was a standard director compensation grant rather than an open market purchase.
Key Transaction Details:
- Transaction Type: Stock Award (Code A)
- Ownership Type: Direct
- Role: Director
- Total Value of Transaction: $145,251.96
CME Group director Daniel G. Kaye reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Kaye now beneficially owns 4,200 shares directly. The filing indicates this was a planned acquisition under the company's director compensation program rather than an open market purchase.
- Transaction Type: Stock Grant (Code A)
- Reporting Person Role: Director
- Ownership Form: Direct
- Filing was submitted by Jenelle Chalmers on behalf of Daniel G. Kaye
FAQ
What is the current stock price of CME Group (CME)?
What is the market cap of CME Group (CME)?
What does CME Group do?
How does CME Group generate revenue?
What is CME Globex?
What is CME Clearing?
What are some key products offered by CME Group?
How does CME Group support sustainability?
What is CME Group's global reach?
Who are CME Group's customers?
What role does CME Group play in financial markets?
How does CME Group differentiate itself from competitors?
